Why Is Dipyrone Banned? | Safety Risks Explained

People often hear about dipyrone, also known as metamizole, from friends or relatives abroad and then discover that pharmacies in their own country do not stock it at all. In some places it is sold on prescription or even over the counter, while in others it disappeared decades ago. This uneven picture confuses many patients who only want reliable pain relief without unexpected danger.

This article explains why some regulators banned dipyrone, why others still allow it, and how current research views its safety profile. You will see how rare but severe blood disorders, differences between health systems, and the availability of other painkillers all feed into these decisions. The goal is to help you understand the reasoning so you can have a clear conversation with your own doctor or pharmacist.

What Is Dipyrone And Where Is It Used?

Dipyrone is a non-opioid painkiller with fever-reducing and antispasmodic effects. Under the name metamizole it has been used for acute pain after surgery, severe toothache, colic, cancer pain, and fever that does not respond to other medicines. In countries where it remains on the market, doctors may use it as tablets, drops, or injections in hospitals.

Many English-speaking countries removed this drug decades ago. The United States withdrew approval in the late 1970s after reports of serious blood reactions called agranulocytosis, which involves a sharp fall in certain white blood cells and can lead to severe infections. Sweden, the United Kingdom, and several other European countries also stopped sales for the same reason.

On the other side, dipyrone continues to be part of routine practice in countries such as Germany, Spain, Brazil, and Mexico, often as a prescription medicine. There, authorities judge that the benefits for short-term severe pain outweigh the rare harms, especially when doctors follow clear dosing rules and watch for warning signs. The result is a world where the same drug is viewed as too risky in some places and reasonably safe in others.

Why Is Dipyrone Banned? Safety Concerns Behind The Decision

Regulators who banned dipyrone usually point to one main concern: unpredictable blood toxicity. The best known problem is agranulocytosis, where the body suddenly produces far fewer neutrophils, a type of white blood cell that fights bacteria. Without enough neutrophils, even small infections can progress quickly and become life-threatening.

Several classic studies from the twentieth century linked dipyrone to cases of agranulocytosis. A large international case-control study in the 1980s, summarised in a WHO Pharmaceuticals Newsletter, suggested a higher rate of this reaction among people who took the drug, especially in some northern European populations. Later reports from Sweden and other countries described further clusters, which reinforced concern among regulators in those regions.

The challenge lies in how rare and unpredictable these reactions are. For most users, dipyrone works as a strong painkiller without any serious problem. For a very small number of people, though, it may trigger a sudden and severe reaction that can lead to sepsis or death if treatment is delayed. Because routine life does not allow blood tests every few days, regulators in some countries concluded that avoiding the drug entirely was safer than trying to manage this small but severe risk.

Agranulocytosis And Other Serious Side Effects

Agranulocytosis is not the only worry. Reports describe other severe reactions such as aplastic anaemia, in which the bone marrow stops producing enough blood cells, and life-threatening allergic reactions with rash, breathing difficulty, or shock. Some case reports and the NIH LiverTox review also mention rare liver injury linked to dipyrone.

Modern reviews give a mixed picture. Some meta-analyses suggest that, dose for dose, dipyrone causes fewer stomach and kidney problems than common non-steroidal anti-inflammatory drugs like ibuprofen or aspirin. At the same time, they confirm that serious blood disorders, while uncommon, remain a real concern. This tension between everyday tolerability and rare but severe reactions helps explain why national policies diverge.

Public trust also plays a role. Once a drug acquires a reputation for severe reactions, reversing a ban becomes politically and socially difficult, even if later data suggest that the absolute risk might be low in some settings. Health agencies must weigh not only statistics but also the message they send to the public by reinstating or maintaining such a medicine.

How Different Countries Handle Dipyrone Today

The legal status of dipyrone now varies across the globe. Some countries prohibit it completely, some allow it only in hospitals, and others treat it as a regular prescription painkiller. To manage ongoing concern about agranulocytosis, several European regulators have updated product information, dosing limits, and monitoring advice in recent years. The European Medicines Agency has run repeated reviews to refine these measures and reduce the chance of severe blood reactions.

The table below gives a broad, simplified view of how different regions treat this drug. Exact rules change over time, so local guidance always takes priority, yet this snapshot helps show why travellers and migrants may encounter conflicting messages about the same medicine.

Country/Region	Status	Typical Setting
United States	Banned/withdrawn	Not available for human use; approved only for certain veterinary uses
United Kingdom & Ireland	Not licensed	No authorised human products; occasional references in older literature
Sweden & Some Nordic States	Withdrawn	Historic ban after agranulocytosis reports
Germany	Prescription only	Hospital and outpatient use with warnings and monitoring advice
Spain	Prescription only	Commonly used for acute pain; regulators emphasise vigilance
Brazil & Mexico	Widely available	Often used for fever and pain, sometimes over the counter
India	Mixed history	Past bans and re-introductions; current status depends on national rulings

These differences create a practical issue: people who grew up in a country where dipyrone is common may carry it with them when they move abroad, without realising that it is unapproved in their new home. In the United States, surveys of Latino immigrants found that a substantial share had brought dipyrone products from abroad and continued to use them, sometimes without telling their doctors.

From a regulatory point of view, bans in countries such as the United States and Sweden were driven by earlier studies that suggested an increased incidence of agranulocytosis in those populations. Later research hinted that risk may vary by genetics and patterns of use, but that does not erase the earlier experience. Health agencies must weigh local data, health system capacity, and availability of alternatives such as paracetamol and ibuprofen when setting policy.

What Research Says About Dipyrone Safety

Over the past two decades, several research groups have revisited the safety of dipyrone using both observational data and pharmacovigilance databases. A large systematic review in 2015, published as a retrospective analysis of spontaneous reports, looked at reports of blood disorders linked to the drug and confirmed that such reactions, while rare, can be severe and sometimes fatal. National pharmacovigilance centres have reached similar conclusions when they review their own case series.

Other researchers compared dipyrone with over-the-counter painkillers such as paracetamol and aspirin. One meta-analysis published in 2025 found that single doses of dipyrone caused fewer common side effects than those older drugs, yet the authors still flagged agranulocytosis as a feared complication that requires respect and awareness.

Regulators in Europe continue to respond to this evolving evidence. In 2024 the European Medicines Agency began another review of metamizole-containing medicines, questioning whether existing risk minimisation steps, such as warnings and blood test advice, are enough to catch early cases of agranulocytosis. The agency later endorsed new measures intended to raise awareness of warning signs and tighten use in certain groups.

At the same time, specialists from the Irish Pain Society and other groups have urged caution for populations that may be more susceptible to this reaction, pointing to epidemiological data from the United Kingdom, Ireland, and Scandinavia. Their statements recommend close monitoring, regular blood counts during longer treatment, and careful patient selection wherever the drug remains on the market.

Source	Main Finding	Practical Message
International Agranulocytosis Study	Linked dipyrone use to higher rates of agranulocytosis in some regions	Prompted early bans and strict regulatory action
Swedish Safety Studies	Reported raised incidence of blood disorders in users	Led to withdrawal in Sweden and influenced nearby countries
Systematic Review (2015)	Confirmed rare but severe haematological reactions	Called for careful risk–benefit assessment and monitoring
Recent Meta-analysis (2025)	Found fewer routine side effects than paracetamol or aspirin	Everyday tolerability good; rare blood events still a concern
EMA Reviews (2018–2024)	Recognised agranulocytosis as a known risk	Recommended clearer warnings and stricter safeguards
Irish Pain Society Statement	Suggested higher susceptibility in some northern European groups	Advised tight monitoring and cautious use where authorised
NIH LiverTox Profile	Described occasional liver injury cases alongside other risks	Reinforced need to look for both blood and liver problems

Why Some Countries Still Use Dipyrone

Given all these safety worries, people often wonder why dipyrone remains popular in parts of Europe and Latin America. Doctors in those regions point to its strong pain relief, low cost, and lack of certain side effects seen with non-steroidal anti-inflammatory drugs, such as stomach bleeding or kidney strain. In busy emergency departments, an intravenous dose can bring quick relief when other options have not worked.

Health authorities that allow dipyrone often argue that outright bans push patients toward opioids for severe pain, which bring their own problems, including dependence and overdose. In that context, a non-opioid drug with rare but manageable risks can appear attractive, especially if use is brief and monitored. Some reviews even describe metamizole as having a safety profile that compares well with older painkillers when used correctly.

That said, these same agencies still advise strict precautions. Many restrict dipyrone to prescription status, recommend avoiding it in pregnancy or in people with previous blood disorders, and call for patients to seek urgent medical attention if they notice fever, sore throat, mouth ulcers, or other signs of infection during treatment. Frequent safety reviews and updated product information sheets underline that this is not a casual everyday painkiller.

What To Do If You Are Offered Dipyrone

People may encounter dipyrone while travelling, during hospital stays abroad, or when receiving medicines sent by relatives from another country. If a clinician suggests this drug, the first step is to ask why it has been chosen instead of more familiar options such as paracetamol or ibuprofen. In some cases, severe pain, high fever, or intolerance to other drugs may justify its use under close supervision.

Anyone with a history of blood disorders, autoimmune disease affecting the bone marrow, or previous unexplained reactions to medicines should tell their doctor before taking dipyrone. Age, other medicines, and underlying illness also matter because they can shape the overall risk picture. A short course in a monitored setting may make sense for one person and not for another.

While taking dipyrone, new symptoms such as high fever, chills, sore throat, painful mouth ulcers, unusual tiredness, dark urine, or yellowing of the skin need urgent attention. These changes can point to infections, blood problems, or liver injury. Medical teams often order a full blood count and liver tests in this situation and will stop the drug immediately if they suspect a reaction.

This article cannot replace individual medical advice. Local rules, available alternatives, and your own health history all influence whether dipyrone is a reasonable choice. Decisions about strong painkillers always belong to a conversation with a qualified professional who knows your case.

Alternatives To Dipyrone For Pain And Fever

In countries where dipyrone is banned, doctors rely on other well-known medicines for pain and fever. Paracetamol (also called acetaminophen) remains the first choice for many mild to moderate problems, as long as the total daily dose stays within safe limits to protect the liver. Non-steroidal anti-inflammatory drugs such as ibuprofen or naproxen add anti-inflammatory action that can help with arthritis, injuries, or menstrual cramps, though they can irritate the stomach and affect the kidneys.

For severe pain after surgery, trauma, or advanced cancer, short-term use of opioids may be necessary. Health professionals weigh the benefits of pain control against the risks of dependence, drowsiness, and breathing problems, and they often combine opioids with non-opioid drugs to reduce doses.

Non-drug measures also play an obvious role in day-to-day pain management. Rest, ice or heat packs, gentle movement, physical therapy, dental care, and other targeted treatments can reduce the need for strong medicines. The best choice depends on the cause of pain, other illnesses, and the setting where care takes place.

Across these options, the thread is the same: use the lowest effective dose for the shortest possible time, and tell your medical team about all medicines you take, including products bought abroad or online. That approach reduces the chance of hidden interactions and helps doctors choose pain relief that matches both your symptoms and local safety standards.